伊沙匹隆杂质2 | 1220999-07-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酯类和类似物
• 中文名称: 伊沙匹隆杂质2
• 英文名称: (Z)-Ixabepilone
• 英文别名: (1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(Z)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione
• CAS: 1220999-07-4
• 化学式: C₂₇H₄₂N₂O₅S
• 分子量: 506.7
• InChiKey: FABUFPQFXZVHFB-UFMFRQELSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  35
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  140
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• Material and methods for treating or preventing HER-3 associated diseases
  申请人：U3 Pharma GmbH

  公开号：EP2719708A2

  公开（公告）日：2014-04-16

  Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.

  本文描述了通过施用与HER-3结合的第一种制剂和与HER家族另一成员结合和/或抑制该成员的第二种制剂，治疗患有HER-3相关疾病的受试者的材料和方法。第一种药剂和第二种药剂可以是生物制剂，例如抗原结合蛋白或小分子酪氨酸激酶抑制剂。
• COMBINATION OF IPILIMUMAB AND PACLITAXEL FOR THE TREATMENT OF CANCER
  申请人：Bristol-Myers Squibb Company

  公开号：EP2962731A1

  公开（公告）日：2016-01-06

  Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.

  本研究公开了有助于治疗和预防增殖性疾病的组合物和方法。
• Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors
  申请人：Aoki Yuko

  公开号：US20050118600A1

  公开（公告）日：2005-06-02

  Based on drug sensitivity data and extensive gene expression data, a model was constructed by multivariate analysis with the partial least squares method type 1. Further, the model was optimized using modeling power and genetic algorithm. Thereby, the degree of contribution of the respective genes to drug sensitivity was determined to select genes with a high degree of contribution. In addition, the levels of gene expression in specimens were analyzed, and then the drug sensitivity was predicted based on the model. The predicted values agreed well with those drug sensitivity values determined experimentally. The drug sensitivity-predicting method provided by the present invention enables assessment of the effectiveness of a drug prior to administration using small quantities of specimens associated with diseases such as cancer. Since this enables the selection of the most suitable drug for each patient, the present invention is very useful in improving a patient's quality of life (QOL).

  根据药物敏感性数据和大量基因表达数据，通过偏最小二乘法 1 型多变量分析构建了一个模型。此外，还利用建模能力和遗传算法对模型进行了优化。据此，确定了各基因对药物敏感性的贡献程度，以选择贡献程度高的基因。此外，还分析了标本中基因的表达水平，然后根据模型预测了药物敏感性。预测值与实验测定的药物敏感性值非常吻合。通过本发明提供的药物敏感性预测方法，可以在用药前使用与癌症等疾病相关的少量标本来评估药物的有效性。这样就能为每位患者选择最合适的药物，因此本发明对提高患者的生活质量（QOL）非常有用。
• [EN] PROCESS FOR THE PREPARATION OF (1S,3S,7S,10R,11S,12S,16R)-7,11-DIHYDROXY-8,8,10,12,16-PENTAMETHYL-3-[(1E)-1-METHYL-2-(2-METHYL-4-THIAZOLYL)ETHENYL]-17-OXA-4-AZABICYCLO[14.1.0]HEPTADECANE-5,9-DIONE AND INTERMEDIATES THEREOF<br/>[FR] PROCÉDÉ DE PRÉPARATION DE (1S,3S,7S,10R,11S,12S,16R)-7,11-DIHYDROXY-8,8,10,12,16-PENTAMÉTHYL-3-[(1E)-1-MÉTHYL-2-(2-MÉTHYL-4-THIAZOLYL)ÉTHÉNYL]-17-OXA-4-AZABICYCLO[14.1.0]HEPTADÉCANE-5,9-DIONE ET DE SES INTERMÉDIAIRES
  申请人：MSN LAB PRIVATE LTD

  公开号：WO2015087351A3

  公开（公告）日：2015-12-03
• ABCBI GENOTYPING TO PREDICT MICROTUBULE-STABILIZING-AGENT-INDUCED TOXICITY
  申请人：The Govt. of the USA as Represented by the Secretary of the Dept. of Health and Human Services

  公开号：EP2041312B1

  公开（公告）日：2010-12-01